USA - engelsk - NLM (National Library of Medicine)

sun pharmaceutical industries, inc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination

USA - engelsk - NLM (National Library of Medicine)

kremers urban pharmaceuticals inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 10 mg - methylphenidate hcl extended-release capsules cd is contraindicated in patients with marked anxiety, tension and agitation, since the drug may aggravate these symptoms. methylphenidate hcl extended-release capsules cd is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product. methylphenidate hcl extended-release capsules cd contains sucrose. therefore, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine. methylphenidate hcl extended-release capsules cd is contraindicated in patients with glaucoma. methylphenidate hcl extended-release capsules cd is contraindicated in patients with motor tics or with a family history or diagnosis of tourette's syndrome (see adverse reactions). methylphenidate hcl extended-release capsules cd is contraindicated during treatment with monoamine oxidase inhibitors, and also within a minimum of 14 days following discon

USA - engelsk - NLM (National Library of Medicine)

kremers urban pharmaceuticals inc. - hydrocodone (unii: 6yks4y3wq7) (hydrocodone - unii:6yks4y3wq7), chlorpheniramine (unii: 3u6io1965u) (chlorpheniramine - unii:3u6io1965u) - hydrocodone bitartrate 10 mg in 5 ml - hydrocodone polistirex and chlorpheniramine polistirex pennkinetic extended-release suspension is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older. hydrocodone polistirex and chlorpheniramine polistirex pennkinetic extended-release suspension is contraindicated in patients with a known allergy or sensitivity to hydrocodone or chlorpheniramine. the use of hydrocodone polistirex and chlorpheniramine polistirex pennkinetic extended-release suspension is contraindicated in children less than 6 years of age due to the risk of fatal respiratory depression. hydrocodone polistirex and chlorpheniramine polistirex pennkinetic extended-release suspension is a schedule ii narcotic. psychic dependence, physical dependence and tolerance may develop upon repeated administration of narcotics; therefore, hydrocodone polistirex and chlorpheniramine polistirex pennkinetic extended-release suspension should be prescribed and administere

USA - engelsk - NLM (National Library of Medicine)

kremers urban pharmaceuticals inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 20.8 mg - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product.

Kina - kinesisk - CFDA (药监局 - 中国食品和药物管理局)

kremers urban pharmaceuticals inc. - 胶囊剂 - 0.15g

Kina - kinesisk - CFDA (药监局 - 中国食品和药物管理局)

kremers urban pharmaceuticals inc. - 胶囊剂 - 0.15g

USA - engelsk - NLM (National Library of Medicine)

kremers urban pharmaceuticals inc. - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.5 mg - tacrolimus capsules usp are indicated for the prophylaxis of organ rejection in patients receiving allogeneic kidney transplants. it is recommended that tacrolimus be used concomitantly with azathioprine or mycophenolate mofetil (mmf) and adrenal corticosteroids [see clinical studies (14.1)] . therapeutic drug monitoring is recommended for all patients receiving tacrolimus capsules usp [see dosage and administration (2.6)] . tacrolimus capsules usp are indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver transplants. it is recommended that tacrolimus be used concomitantly with adrenal corticosteroids [see clinical studies (14.2)] . therapeutic drug monitoring is recommended for all patients receiving tacrolimus capsules usp [see dosage and administration (2.6)] . tacrolimus capsules usp are indicated for the prophylaxis of organ rejection in patients receiving allogeneic heart transplants. it is recommended that tacrolimus capsules usp be used concomitantly with azathioprine

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 90 mg - nifedipine extended-release tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine extended-release tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. nifedipine extended-release tablet is indicated for the management of chronic st

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine extended-release tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine extended-release tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. nifedipine extended-release tablet is indicated for the management of chronic st

USA - engelsk - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - nifedipine extended-release tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine extended-release tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. nifedipine extended-release tablet is indicated for the management of chronic st